252 related articles for article (PubMed ID: 36018379)
1. Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?
Schneider CA; Pfister R
Herz; 2022 Oct; 47(5):395-400. PubMed ID: 36018379
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
Jhund PS
Heart Fail Clin; 2022 Oct; 18(4):579-586. PubMed ID: 36216487
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Anker SD; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Zannad F; Packer M;
Eur J Heart Fail; 2019 Oct; 21(10):1279-1287. PubMed ID: 31523904
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
Cohen LP; Isaza N; Hernandez I; Lewis GD; Ho JE; Fonarow GC; Kazi DS; Bellows BK
JAMA Cardiol; 2023 May; 8(5):419-428. PubMed ID: 36870047
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
[TBL] [Abstract][Full Text] [Related]
6. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.
Vaduganathan M; Docherty KF; Claggett BL; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; McMurray JJV; Solomon SD
Lancet; 2022 Sep; 400(10354):757-767. PubMed ID: 36041474
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
Wang Y; Gao T; Meng C; Li S; Bi L; Geng Y; Zhang P
Eur J Med Res; 2022 Dec; 27(1):314. PubMed ID: 36581880
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction.
Pandey AK; Bhatt DL; Pandey A; Marx N; Cosentino F; Pandey A; Verma S
Eur Heart J; 2023 Oct; 44(37):3640-3651. PubMed ID: 37674356
[TBL] [Abstract][Full Text] [Related]
9. Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions.
Passantino A; Rizzo C; Scrutinio D; Palazzuoli A
Heart Fail Rev; 2023 May; 28(3):683-695. PubMed ID: 34725782
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 Inhibitors in Older Adults with Heart Failure with Preserved Ejection Fraction.
Hias J; Hellemans L; Walgraeve K; Tournoy J; Van der Linden L
Drugs Aging; 2022 Mar; 39(3):185-190. PubMed ID: 35118602
[TBL] [Abstract][Full Text] [Related]
11. Sodium-Glucose Co-transporter 2 Inhibitors in Patients with Heart Failure with Preserved Ejection Fraction: Proposed Mechanisms, Recent Evidence, and Clinical Implications.
Plosker A; Frishman WH
Cardiol Rev; 2024 May-Jun 01; 32(3):263-266. PubMed ID: 36728757
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
[TBL] [Abstract][Full Text] [Related]
13. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.
Anker SD; Butler J; Filippatos G; Shahzeb Khan M; Ferreira JP; Bocchi E; Böhm M; Brunner-La Rocca HP; Choi DJ; Chopra V; Chuquiure E; Giannetti N; Gomez-Mesa JE; Janssens S; Januzzi JL; Gonzalez-Juanatey JR; Merkely B; Nicholls SJ; Perrone SV; Piña IL; Ponikowski P; Senni M; Seronde MF; Sim D; Spinar J; Squire I; Taddei S; Tsutsui H; Verma S; Vinereanu D; Zhang J; Jamal W; Schnaidt S; Schnee JM; Brueckmann M; Pocock SJ; Zannad F; Packer M;
Eur J Heart Fail; 2020 Dec; 22(12):2383-2392. PubMed ID: 33251670
[TBL] [Abstract][Full Text] [Related]
14. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
[TBL] [Abstract][Full Text] [Related]
15. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
Nakagawa Y; Kuwahara K
J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
[TBL] [Abstract][Full Text] [Related]
16. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
Lan NSR; Fegan PG; Yeap BB; Dwivedi G
ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
[TBL] [Abstract][Full Text] [Related]
17. Chapter 2: Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection Fraction.
Ostrominski JW; Vaduganathan M
Am J Med; 2024 Feb; 137(2S):S9-S24. PubMed ID: 37160196
[TBL] [Abstract][Full Text] [Related]
18. Management strategies in heart failure with preserved ejection fraction.
Wintrich J; Abdin A; Böhm M
Herz; 2022 Aug; 47(4):332-339. PubMed ID: 35524007
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients.
Kashiwagi A; Araki S; Maegawa H
J Diabetes Investig; 2021 Jan; 12(1):6-20. PubMed ID: 32563214
[TBL] [Abstract][Full Text] [Related]
20. Systematic Review of the Economic Evaluation of Sodium-Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure.
Nam K; Cho DS; Kim H; Kwon B; Yoon Y; Park C; Kim ES; Youn JC; Park SK
Clin Drug Investig; 2023 Jul; 43(7):463-474. PubMed ID: 37365452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]